JPWO2022159653A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022159653A5 JPWO2022159653A5 JP2023544485A JP2023544485A JPWO2022159653A5 JP WO2022159653 A5 JPWO2022159653 A5 JP WO2022159653A5 JP 2023544485 A JP2023544485 A JP 2023544485A JP 2023544485 A JP2023544485 A JP 2023544485A JP WO2022159653 A5 JPWO2022159653 A5 JP WO2022159653A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- bispecific car
- seq
- epc
- signaling domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 19
- 239000000427 antigen Substances 0.000 claims 16
- 102000036639 antigens Human genes 0.000 claims 16
- 108091007433 antigens Proteins 0.000 claims 16
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 150000007523 nucleic acids Chemical class 0.000 claims 12
- 230000011664 signaling Effects 0.000 claims 8
- 210000002865 immune cell Anatomy 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 5
- 102000001301 EGF receptor Human genes 0.000 claims 5
- 108060006698 EGF receptor Proteins 0.000 claims 5
- 230000000139 costimulatory effect Effects 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 4
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 4
- 230000001086 cytosolic effect Effects 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100032937 CD40 ligand Human genes 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- -1 ICOS Proteins 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000009033 hematopoietic malignancy Effects 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163140752P | 2021-01-22 | 2021-01-22 | |
| US63/140,752 | 2021-01-22 | ||
| PCT/US2022/013231 WO2022159653A2 (en) | 2021-01-22 | 2022-01-21 | Bispecific chimeric antigen receptors binding to cd19 and cd22 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024504162A JP2024504162A (ja) | 2024-01-30 |
| JPWO2022159653A5 true JPWO2022159653A5 (https=) | 2025-01-28 |
| JP2024504162A5 JP2024504162A5 (https=) | 2025-01-28 |
Family
ID=82549829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023544485A Pending JP2024504162A (ja) | 2021-01-22 | 2022-01-21 | Ｃｄ１９及びｃｄ２２に結合する二重特異性キメラ抗原受容体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240082402A1 (https=) |
| EP (1) | EP4281470A4 (https=) |
| JP (1) | JP2024504162A (https=) |
| KR (1) | KR20230137948A (https=) |
| CN (1) | CN117062844A (https=) |
| AU (1) | AU2022209703A1 (https=) |
| CA (1) | CA3208935A1 (https=) |
| IL (1) | IL304554A (https=) |
| WO (1) | WO2022159653A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220050182A (ko) * | 2019-08-21 | 2022-04-22 | 엘피스 바이오파마슈티컬즈 | 항-cd22 항체 및 그의 용도 |
| WO2024096522A1 (ko) * | 2022-10-31 | 2024-05-10 | 재단법인 아산사회복지재단 | Cd22에 결합하는 항체, 이를 포함하는 이중특이적 항체, 키메라 항원 수용체, 항체 약물 복합체 및 이의 용도 |
| CN116462770B (zh) * | 2023-04-18 | 2024-03-08 | 科弈(浙江)药业科技有限公司 | Cd19的人源化抗体和一种表达双特异性嵌合抗原受体的car-t细胞及其应用 |
| KR20250174161A (ko) * | 2024-06-04 | 2025-12-12 | 한국과학기술연구원 | 엔도글린 및 메소테린 이중 항원 표적 car 및 이의 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10259874B2 (en) * | 2014-10-27 | 2019-04-16 | Agency For Science, Technology And Research | Anti-TIM-3 antibodies |
| MX2017012939A (es) * | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
| TWI717375B (zh) * | 2015-07-31 | 2021-02-01 | 德商安美基研究（慕尼黑）公司 | Ｃｄ７０及ｃｄ３抗體構築體 |
| CN113286607B (zh) * | 2018-09-26 | 2024-07-12 | 莱蒂恩技术公司 | 用于用抗cd19/cd22免疫治疗来治疗癌症的组合物和方法 |
| US12590386B2 (en) * | 2019-04-30 | 2026-03-31 | Gigagen, Inc. | Recombinant polyclonal proteins and methods of use thereof |
| KR20220048028A (ko) * | 2019-08-19 | 2022-04-19 | 엘피스 바이오파마슈티컬즈 | 항-cd19 항체 및 그의 용도 |
| KR20220050182A (ko) * | 2019-08-21 | 2022-04-22 | 엘피스 바이오파마슈티컬즈 | 항-cd22 항체 및 그의 용도 |
-
2022
- 2022-01-21 WO PCT/US2022/013231 patent/WO2022159653A2/en not_active Ceased
- 2022-01-21 AU AU2022209703A patent/AU2022209703A1/en active Pending
- 2022-01-21 US US18/262,496 patent/US20240082402A1/en active Pending
- 2022-01-21 CA CA3208935A patent/CA3208935A1/en active Pending
- 2022-01-21 EP EP22743215.0A patent/EP4281470A4/en active Pending
- 2022-01-21 KR KR1020237028465A patent/KR20230137948A/ko active Pending
- 2022-01-21 CN CN202280021455.4A patent/CN117062844A/zh active Pending
- 2022-01-21 JP JP2023544485A patent/JP2024504162A/ja active Pending
-
2023
- 2023-07-18 IL IL304554A patent/IL304554A/en unknown